SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes

Core Insights - SAB Biotherapeutics, Inc. announced promising early data from the Phase 1 trial of SAB-142, indicating preservation of C-peptide levels in adult patients with type 1 diabetes (T1D) [2][4][9] Group 1: Clinical Trial Results - In the Phase 1 T1D cohort, four out of six adult participants treated with SAB-142 (2.5 mg/kg) showed no decrease in C-peptide levels at Day 120 compared to baseline, while the placebo group exhibited a decline [2][3] - The mean C-peptide levels in SAB-142 treated participants increased above baseline by Day 120, contrasting with the predicted decline in the placebo group [4][9] - The study included six adult participants aged 19 to 40, all with established T1D and residual beta cell function at baseline [3][4] Group 2: Mechanism of Action and Efficacy - The preservation of C-peptide is a positive clinical marker for endogenous insulin production, suggesting that SAB-142 may modify the disease course in T1D [3][4] - Biomarker evidence indicated T cell exhaustion, supporting the hypothesis that SAB-142 engages its intended biological mechanism [3][4] Group 3: Future Developments - The Phase 1 study met its primary objectives, allowing SAB Biotherapeutics to advance SAB-142 into the registrational Phase 2b SAFEGUARD trial, which aims to evaluate safety and efficacy in new-onset T1D patients [9][14] - Topline data from the SAFEGUARD trial is expected in the second half of 2027, with the trial currently enrolling participants globally [9][14] Group 4: Company Overview - SAB Biotherapeutics is focused on developing multi-specific, high-potency human immunoglobulin G (hIgG) therapies for autoimmune disorders, with SAB-142 as a lead candidate targeting T1D [16] - The company utilizes advanced genetic engineering to produce hIgG without the need for human donors, aiming to address serious unmet medical needs [16]